Actos Bladder Cancer
Actos users with bladder cancer, take heart. Discovered early, the cancer is easily treated.
Bladder cancer most often occurs in the cells lining the bladder, the organ in your pelvis that collects urine from the kidneys. Usually, cell growth is orderly – when old cells die, the body makes new ones to replace them. But with cancer this process goes awry – old cells don't die, and new ones grow uncontrolled.
Bladder cancer is the sixth most-common cancer in the United States, according to the National Cancer Institute. The NCI predicts 73,510 new bladder cancers will be diagnosed in 2012. But who will get it or why isn't known. However, risk factors from age, to chemical exposure, to using drugs like Actos, are associated with the disease. (See FDA warning.)
Although the NCI predicts 14,880 bladder-cancer deaths in 2012, when discovered early, bladder cancer can be successfully treated.
Unfortunately, bladder cancer has the highest recurrence rate among all cancers – from 40 percent to 80 percent, depending on how deeply embedded the cancer is and how aggressively it is growing. As a result, after treatment you'll have to be tested every three to six months for the first four years and then annually after that to find any recurrence quickly when it's most curable. (See Bladder cancer prognosis.)
Actos users facing bladder cancer should keep this ongoing monitoring in mind when considering whether to seek damages against the drugmaker. Remember, ActosLawsuit.com offers you a free case evaluation. Know your options as you face bladder cancer.